IP Library › Granted Patent US 8,722,636
Granted Patent B2
US 8,722,636 · App. 13/343,692 · Granted May 13, 2014

Animal treatments

Inventors: David Rock (Hillsborough, NJ); Mark Ridall (Princeton, NJ)
Assignee: New Market Pharmaceuticals, LLC
A61K31/135A61K31/155
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,722,636
App. No.
13/343,692
Granted
May 13, 2014
Kind
B2
Abstract

Compositions and methods for the treatment and control of various conditions in an animal which comprises administering to said animal an effective amount of a immediate release composition of about 0.5% to 50% wt/wt of active ingredient together with excipients to a total of about 100%, wherein said compositon dissolves in a relatively short period of time, e.g., 75 seconds or less, 5 seconds or less, or 3 seconds or less, upon administration to said animal.

Claims (14)

1. A method of treating gastric ulcers in an animal in need thereof, comprising:

determining a dose of omeprazole required;

administering orally to a pre-gastric mucosal cell of said animal, a Direct Systemic Introduction (DSI) composition comprising omeprazole;

wherein the DSI composition in the animal's oral cavity is dissolved in 30 seconds or less;

wherein greater than 50% of the administered omeprazole is absorbed into the animal's circulatory system in the pre-gastric mucosal cells lining the animal's alimentary canal; and

wherein the pH of the composition is between 6 to 10.

2. The method of claim 1 , wherein the animal is an equine.

3. A method of suppressing gastric acidity in an animal in need thereof, comprising:

determining a dose of omeprazole required;

administering orally to a pre-gastric mucosal cell of said animal, a Direct Systemic Introduction (DSI) composition comprising omeprazole;

wherein the DSI composition in the animal's oral cavity is dissolved in 30 seconds or less;

wherein greater than 50% of the administered omeprazole is absorbed into the animal's circulatory system in the pre-gastric mucosal cells lining the animal's alimentary canal; and

wherein the pH of the composition is between 6 to 10.

4. The method of claim 3 , wherein the animal is an equine.

Assignments (9)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2019
From: RIDALL, MARK
To: NEWMARKET PHARMACEUTICALS LLC
Reel/Frame 050714/0222 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PRTY TO NEWMARKET PHARMACEUTICALS LLC AND RECEIVING PRTY TO VETBRIDGE PRODUCT DEVELOPMENT SUBSIDIARY I (NM-OMP), LLC PREVIOUSLY RECORDED ON REEL 047254 FRAME 0898. ASSIGNOR(S) HEREBY CONFIRMS THE THE EXCLUSIVE DISTRIBUTION AND LICENSE AGREEMENT.. Recorded Jul 26, 2019
From: NEWMARKET PHARMACEUTICALS LLC
To: VETBRIDGE PRODUCT DEVELOPMENT SUBSIDIARY I (NM-OMP), LLC
Reel/Frame 049888/0847 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT THE PATENT NO: PREVIOUSLY RECORDED AT REEL: 046924 FRAME: 0600. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Feb 28, 2019
From: NEWMARKET PHARMACEUTICALS LLC
To: RIDALL, MARK
Reel/Frame 048467/0351 →
EXCLUSIVE DISTRIBUTION AND LICENSE AGREEMENT Recorded Jul 17, 2018
From: VETBRIDGE PRODUCT DEVELOPMENT SUBSIDIARY
To: NEWMARKET PHARMACEUTICALS LLC
Reel/Frame 047254/0898 →
CONVERTIBLE PROMISSORY NOTE Recorded Sep 27, 2017
From: NEW MARKET PHARMACEUTICALS, LLC
To: RIDALL, MARK
Reel/Frame 044029/0113 →
LICENSE Recorded Oct 10, 2014
From: NEW MARKET PHARMACEUTICALS, LLC
To: VETBRIDGE PRODUCT DEVELOPMENT SUBSIDIARY I, LLC
Reel/Frame 033930/0226 →
RELEASE OF SECURITY INTEREST Recorded May 23, 2014
From: MCDONALD, BRIAN
To: NEWMARKET PHARMACEUTICALS LLC
Reel/Frame 033005/0396 →
SECURITY AGREEMENT Recorded Sep 5, 2013
From: NEWMARKET PHARMACEUTICALS LLC
To: MCDONALD, BRIAN
Reel/Frame 031157/0281 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2012
From: ROCK, DAVID; RIDALL, MARK
To: NEWMARKET PHARMACEUTICALS, LLC
Reel/Frame 028035/0012 →
Continuity (2)
Provisional Application 61437763 · Jan 31, 2011
Related Publication 20120196819A1 · Aug 2, 2012